Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,175 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase I study of GTI-2040, a ribonucleotide reductase antisense, with high dose cytarabine in patients with relapsed/refractory acute myeloid leukemia.
Klisovic RB, Blum W, Liu Z, Xie Z, Kefauver C, Huynh L, Zwiebel JA, Devine SM, Byrd JC, Grever MR, Chan KK, Marcucci G. Klisovic RB, et al. Among authors: chan kk. Leuk Lymphoma. 2014 Jun;55(6):1332-6. doi: 10.3109/10428194.2013.838764. Epub 2013 Nov 1. Leuk Lymphoma. 2014. PMID: 24015841 Free PMC article. Clinical Trial.
Phase I study of GTI-2040, an antisense to ribonucleotide reductase, in combination with high-dose cytarabine in patients with acute myeloid leukemia.
Klisovic RB, Blum W, Wei X, Liu S, Liu Z, Xie Z, Vukosavljevic T, Kefauver C, Huynh L, Pang J, Zwiebel JA, Devine S, Byrd JC, Grever MR, Chan K, Marcucci G. Klisovic RB, et al. Clin Cancer Res. 2008 Jun 15;14(12):3889-95. doi: 10.1158/1078-0432.CCR-08-0109. Clin Cancer Res. 2008. PMID: 18559610 Free PMC article. Clinical Trial.
Phase I study of oblimersen sodium, an antisense to Bcl-2, in untreated older patients with acute myeloid leukemia: pharmacokinetics, pharmacodynamics, and clinical activity.
Marcucci G, Stock W, Dai G, Klisovic RB, Liu S, Klisovic MI, Blum W, Kefauver C, Sher DA, Green M, Moran M, Maharry K, Novick S, Bloomfield CD, Zwiebel JA, Larson RA, Grever MR, Chan KK, Byrd JC. Marcucci G, et al. Among authors: chan kk. J Clin Oncol. 2005 May 20;23(15):3404-11. doi: 10.1200/JCO.2005.09.118. Epub 2005 Apr 11. J Clin Oncol. 2005. PMID: 15824414 Clinical Trial.
Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia.
Blum W, Klisovic RB, Hackanson B, Liu Z, Liu S, Devine H, Vukosavljevic T, Huynh L, Lozanski G, Kefauver C, Plass C, Devine SM, Heerema NA, Murgo A, Chan KK, Grever MR, Byrd JC, Marcucci G. Blum W, et al. Among authors: chan kk. J Clin Oncol. 2007 Sep 1;25(25):3884-91. doi: 10.1200/JCO.2006.09.4169. Epub 2007 Aug 6. J Clin Oncol. 2007. PMID: 17679729 Clinical Trial.
Targeted delivery of antisense oligodeoxynucleotide by transferrin conjugated pH-sensitive lipopolyplex nanoparticles: a novel oligonucleotide-based therapeutic strategy in acute myeloid leukemia.
Jin Y, Liu S, Yu B, Golan S, Koh CG, Yang J, Huynh L, Yang X, Pang J, Muthusamy N, Chan KK, Byrd JC, Talmon Y, Lee LJ, Lee RJ, Marcucci G. Jin Y, et al. Among authors: chan kk. Mol Pharm. 2010 Feb 1;7(1):196-206. doi: 10.1021/mp900205r. Mol Pharm. 2010. PMID: 19852511 Free PMC article.
Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine.
Blum W, Garzon R, Klisovic RB, Schwind S, Walker A, Geyer S, Liu S, Havelange V, Becker H, Schaaf L, Mickle J, Devine H, Kefauver C, Devine SM, Chan KK, Heerema NA, Bloomfield CD, Grever MR, Byrd JC, Villalona-Calero M, Croce CM, Marcucci G. Blum W, et al. Among authors: chan kk. Proc Natl Acad Sci U S A. 2010 Apr 20;107(16):7473-8. doi: 10.1073/pnas.1002650107. Epub 2010 Apr 5. Proc Natl Acad Sci U S A. 2010. PMID: 20368434 Free PMC article. Clinical Trial.
Phase I trial of low dose decitabine targeting DNA hypermethylation in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: dose-limiting myelosuppression without evidence of DNA hypomethylation.
Blum KA, Liu Z, Lucas DM, Chen P, Xie Z, Baiocchi R, Benson DM, Devine SM, Jones J, Andritsos L, Flynn J, Plass C, Marcucci G, Chan KK, Grever MR, Byrd JC. Blum KA, et al. Among authors: chan kk. Br J Haematol. 2010 Jul;150(2):189-95. doi: 10.1111/j.1365-2141.2010.08213.x. Epub 2010 Apr 29. Br J Haematol. 2010. PMID: 20456354 Free PMC article. Clinical Trial.
Clinical and pharmacodynamic activity of bortezomib and decitabine in acute myeloid leukemia.
Blum W, Schwind S, Tarighat SS, Geyer S, Eisfeld AK, Whitman S, Walker A, Klisovic R, Byrd JC, Santhanam R, Wang H, Curfman JP, Devine SM, Jacob S, Garr C, Kefauver C, Perrotti D, Chan KK, Bloomfield CD, Caligiuri MA, Grever MR, Garzon R, Marcucci G. Blum W, et al. Among authors: chan kk. Blood. 2012 Jun 21;119(25):6025-31. doi: 10.1182/blood-2012-03-413898. Epub 2012 May 7. Blood. 2012. PMID: 22566605 Free PMC article. Clinical Trial.
Phase 1 and pharmacodynamic studies of G3139, a Bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukemia.
Marcucci G, Byrd JC, Dai G, Klisovic MI, Kourlas PJ, Young DC, Cataland SR, Fisher DB, Lucas D, Chan KK, Porcu P, Lin ZP, Farag SF, Frankel SR, Zwiebel JA, Kraut EH, Balcerzak SP, Bloomfield CD, Grever MR, Caligiuri MA. Marcucci G, et al. Among authors: chan kk. Blood. 2003 Jan 15;101(2):425-32. doi: 10.1182/blood-2002-06-1899. Epub 2002 Aug 22. Blood. 2003. PMID: 12393493 Free article. Clinical Trial.
A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia.
Byrd JC, Marcucci G, Parthun MR, Xiao JJ, Klisovic RB, Moran M, Lin TS, Liu S, Sklenar AR, Davis ME, Lucas DM, Fischer B, Shank R, Tejaswi SL, Binkley P, Wright J, Chan KK, Grever MR. Byrd JC, et al. Among authors: chan kk. Blood. 2005 Feb 1;105(3):959-67. doi: 10.1182/blood-2004-05-1693. Epub 2004 Oct 5. Blood. 2005. PMID: 15466934 Free article. Clinical Trial.
1,175 results